HOUSTON , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that it will present at Cowen and Company's 40th Annual Health Care Conference in Boston, MA. Event: Cowen & Company 40th Annual Health Care Conference Presentation
Dose escalation of AVB-500 to 20mg/kg dose follows positive recommendation by independent Data Monitoring Committee review Plan to initiate Phase 2/3 study in Platinum Resistant Ovarian Cancer by year end 2020 HOUSTON , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc.
HOUSTON , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) has cleared the company’s Investigational New Drug (IND) application for investigation of the company’s lead
Rekha Hemrajani Appointed President, Chief Executive Officer and Director to Execute Corporate Strategy as Company Advances Clinical Pipeline Jay Shepard to Assume Role of Chairman of the Board of Directors HOUSTON , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage
HOUSTON , Dec. 20, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling patients in the Phase 2a clinical trial of AVB-500 in patients with kidney fibrosis, specifically IgA Nephropathy (IgAN)
HOUSTON , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that company management will participate at the
HOUSTON , Nov. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) , (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced the pricing of its previously
HOUSTON , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) , (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that it has commenced an underwritten
Statistically significant four-fold increase in progression free survival observed in women with high AVB-500 levels Progression Free Survival of AVB-500 over time in Days Aravive to Host Conference Call Today at 8 a.m. EST HOUSTON, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc.
Investigator-sponsored study being conducted in clinical collaboration with Aravive and AstraZeneca HOUSTON and WILMINGTON, Del. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) and AstraZeneca (NYSE: AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of
